# Online Resource for:

# Pragmatic modeling supports current dosing guidelines for carbamazepine and valproic acid for the treatment of epilepsy in children

Joyce E.M. van der Heijden<sup>1</sup>, Violette Gijsen<sup>1</sup>, Anne M. van Uden<sup>1</sup>, Marika de Hoop-Sommen<sup>1</sup>, Jolien J.M. Freriksen<sup>1</sup>, Elke Jacobs<sup>2</sup>, Rick Greupink<sup>1,</sup> Saskia N. de Wildt<sup>1,3</sup>

*<sup>1</sup>Division of Pharmacology and Toxicology, Department of Pharmacy, Radboud university medical center, Nijmegen, The Netherlands; <sup>2</sup>HagaZiekenhuis-Juliana's Childrens hospital; <sup>3</sup>Department of Neonatal and Pediatric Intensive Care, Division of Pediatric Intensive care, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands*

Corresponding author – Prof. dr. Saskia N. de Wildt, Saskia.deWildt@radboudumc.nl.

# **Content**



# <span id="page-1-1"></span><span id="page-1-0"></span>1. Model input parameters

Table 1. Drug-dependent input parameters for carbamazepine (CBZ) and carbamazepine-10,11-epoxide (CBZE)





Table 2. Drug-dependent input parameters for valproic acid (VPA) immediate-release (IR), VPA extended release (ER), and 4-ene-VPA

\*Interpolation method: Piecewise Cubic Polynomial. Abbreviations: divalproex sodium (DVS), sodium valproate (NaVPA).



Figure 1. CYP and UGT ontogeny profiles. Equations: CYP2C8 activity below 20 years = 0.41 + (((1.053 - $(0.41)^*$ Age<sup>0.68</sup>) /  $(0.366^{0.68} + Age^{0.68})$ ; CYP2C9 activity below 5 years = 0.17 + (((0.98 - 0.17)\*Age<sup>0.53</sup>) /  $(0.0157^{0.53} + Age^{0.53}))$ ; CYP3A4 activity below 2.5 years = 0.15 +  $(((1.7 - 0.15)*Age^{1.3}) / (0.1^{1.3} + Age^{1.3}))$ and CYP3A4 activity above 2.5 years =  $0.7 + 1*$ exp<sup>-0.01\*</sup><sup>(Age-0.5)</sup>; UGT1A4 activity below 20 years = 0.05 +  $(((1.028 - 0.05) * Age^{1.36}) / (1.042^{1.36} + Age^{1.36}))$ ; UGT1A6 activity below 15 years = 0.142 +  $(((1.025 (0.142)^*$ Age<sup>0.97</sup>) /  $(0.411^{0.97} + Age^{0.97})$ ; UGT1A9 activity below 0.16 years = 0.0541 + (((1.012 - $(0.0541)^*$ Age<sup>5.771</sup>) /  $(0.07228^{5.771} +$  Age<sup>5.771</sup>)); UGT2B7 activity below 21 years = 0.113 + 0.0425\*Age.

# 2. Search strategies

The PubMed database was searched for carbamazepine (CBZ) and valproic acid (VPA) adult and pediatric pharmacokinetic (PK) data. Both the drugname and brandname are included in the search queries. For CBZ the terms 'Carbamazepine' and 'Tegretol' were included and for VPA the terms 'Valproic Acid', 'Depakine', 'Depakote', 'Valproate', and 'VPA' Titles and abstracts of all search results were screened to check if actual PK data were provided in the publication. To extend our search strategy, the 'Similar articles' overview and references were checked to identify relevant articles which were missed with the initial search queries.

### Search query for healthy volunteer PK studies:

((Pharmacokinet\*[Title/Abstract]) AND (*DRUGNAME*\*[Title] OR *BRANDNAME*\*[Title]) AND (Healthy[Title] OR volunteer\*[Title] OR adult\*[Title] OR subject\*[Title] OR Man[Title] OR Men[Title] OR Woman[Title] OR Women[Title] OR male\*[Title] OR female\*[Title])) OR (("Pharmacokinetics of"[Title]) AND ("*DRUGNAME*"[Title] OR "*BRANDNAME*"[Title]) OR ("*DRUGNAME* pharmacokinetics"[Title]))

 $CBZ \to 176$  results (01-08-2023)  $VPA \rightarrow 264$  results (19-12-2023)

## Search query for pediatric PK studies:

(Pharmacokinet\*[Title/Abstract]) AND (*DRUGNAME*\*[Title] OR *BRANDNAME*\*[Title]) AND (Infan\*[Title] OR newborn\*[Title] OR new-born\*[Title] OR perinat\*[Title] OR neonat\*[Title] OR baby[Title] OR baby\*[Title] OR babies[Title] OR prematur\*[Title] OR preterm\*[Title] OR toddler\*[Title] OR minors[Title] OR minors\*[Title] OR boy[Title] OR boys[Title] OR boyfriend[Title] OR boyhood[Title] OR girl\*[Title] OR kid[Title] OR kids[Title] OR child[Title] OR child\*[Title] OR children\*[Title] OR schoolchild\*[Title] OR schoolchild[Title] OR school child[Title] OR school child\*[Title] OR adolescen\*[Title] OR juvenil\*[Title] OR youth\*[Title] OR teen\*[Title] OR under\*age\*[Title] OR pubescen\*[Title] OR pediatrics[MeSH] OR pediatric\*[Title] OR paediatric\*[Title] OR peadiatric\*[Title])

 $CBZ \rightarrow 37$  results (01-08-2023)  $VPA \rightarrow 82$  results (19-12-2023)

# 3. Pharmacokinetic studies

Table 3. Selected adult single-dose pharmacokinetic studies for carbamazepine model verification.



<span id="page-5-0"></span>Abbreviations: intravenously (IV), not specified (NS), number (N), reference (Ref), every 12 hours (q12h).



Table 4. Selected adult multi-dose pharmacokinetic studies for carbamazepine model verification.

\*i.e., partial seizures with complex symptomatology [e.g., psychomotor, temporal lobe], generalized tonic–clonic seizures [i.e., grand mal], mixed seizure patterns that include one of the previous seizure types, or other partial or generalized seizures. Abbreviations: two times a day (bid), day (d), intravenously (IV), not specified (NS), number (N), every day (qd), reference (Ref), every x hours (qxh).

Table 5. Selected pediatric pharmacokinetic single-dose studies for carbamazepine model verification



Abbreviations: days (d), gestational age (GA), number (N), neonatal intensive care unit (NICU), postnatal age (PNA), reference (Ref), weeks (w), year (y).



# Table 6. Selected pediatric pharmacokinetic multi-dose studies for carbamazepine model verification

aAverage dose (range) Abbreviations: Controlled-release (CR), Generalised tonic-clonic seizures (GTCS), Elementary partial epileptic seizures (EPS), Complex partial epileptic seizures (CPS), Immediate-release (IR), every x hour (qxh), number (N), reference (Ref).



Table 7. Selected adult pharmacokinetic studies for valproic acid immediate-release model verification

Abbreviations: acute myeloid leukemia (AML), intravenous (IV), not specified (NS), number (N), reference (Ref), every x hours (qxh).



Table 8. Selected pediatric pharmacokinetic studies for valproic acid immediate release model verification

<sup>a</sup>lt is assumed that sodium VPA is administered. Abbreviations: central nervous system (CNS), intravenous (IV), not specified (NS), number (N), reference (Ref), every x hours (qxh).



Table 9. Selected adult pharmacokinetic studies for valproic acid extended-release formulation model verification

Abbreviations: controlled-release (CR), extended-release (ER), intravenously (IV), not specified (NS), number (N), reference (Ref), sustained-release (SR), every x hours (qxh).

#### Table 10. Selected pediatric pharmacokinetic studies for valproic acid extended-release model verification



Abbreviations: attention-deficit hyperactivity disorder (ADHD), intravenously (IV), not specified (NS), number (N), reference (Ref), every x hours (qxh).

### <span id="page-11-0"></span>4. Model verification

#### 4.1 Model verification workflow and model performance assessment

Before model application, model performance need to be assessed via model verification. The verification workflow has been published earlier following a pragmatic approach (66, 67). In short, the CBZ and VPA PBPK models, as well as their metabolites, CBZE and 4-ene-VPA, respectively, were verified in the adult population. Simulations upon intravenous (IV) and oral (PO) administration (single and multidose) were compared with published PK data (Table S3, 4, 7 and 9). All simulations were conducted with 10 virtual subjects in 10 trials (i.e., n=100), unless stated otherwise below. In case steady state CBZ concentrations were obtained while no specific sampling day was indicated in the study, it was decided to run the simulations for 31 days and to compare the observed data with the predicted data from the last day.

Of note, for simulations where a 'Custom dosing scheme' or IV administration was applicable (also in simulations with children), CBZ was included in Simcyp as an 'Inhibitor' with CBZE as the 'Inhibitor Metabolite'. As CBZE elimination is partly parameterized as an Oral In Vivo Clearance (Table S1) was it incompatible with the custom dosing functionality when incorporated as 'Sub 1 Met'. The default Alfentanil model was applied as substrate, because there is no interaction between alfentanil and CBZ. Hence, alfentanil has no impact on predicted CBZ concentrations.

Next, simulations with pediatrics receiving IV or PO administrations were conducted and evaluated with clinical data (Table S5, 6, 8 and 10). CYP3A4 is the main metabolizing enzyme of CBZ, whereas VPA is mainly metabolized by UGT's. For CYP2C8, CYP2C9, CYP3A4, UGT1A4, UGT1A6, UGT1A9 and UGT2B7 are ontogeny profiles included (Figure S1), while for CYP3A5, UGT1A8 and UGT1A10 no ontogeny is included (i.e., fraction of adult activity is 1 for all ages). The 'redefine subjects over time' function was activated.

Specific CBZ virtual study designs which were not straight forward:

- For Patsalos et al. (21), four separate simulations were conducted where either 1200, 1400, 1600 or 1800 mg per day was administered orally. Then, plasma concentration-time data were combined to obtain a mean profile of the 4 different dosages to reflect the observed data (n=400).
- For Bertilsson et al. (24), for each separate child, an oral custom dosing scheme was simulated which were as follows: Subject A – Day 1: 2 mg/kg once, day 5-8: 2.62 mg/kg every 12 hours (q12h), day 26-146: 2.43 mg/kg q12h. Subject B – Day 1: 3 mg/kg once, day 5-8: 4.13 mg/kg q12h, day 9-12: 2.08 mg/kg at 9 AM and 4.13 mg/kg at 9 PM, day 13-153: 2.08 mg/kg q12h. Subject  $C - Day 1: 3$  mg/kg once, day 5-38: 1.84 mg/kg at 9 AM and 3.71 mg/kg at 9 PM, day 39-162: 3.45 mg/kg q12h. Individual PK parameters are obtained from these simulations.

- For Camfield et al. (28), three separate simulations are conducted. One to derive PK parameters from (i.e., 6.75 mg/kg q12h) and two to derive individual plasma concentration-time profiles from to match to pediatric subjects (i.e., 200 mg q8h which is 'subject 1' and 200 mg at 9 AM, and 300 mg at 2 and 8 PM which is 'subject 2').

Specific VPA virtual study designs which were not straight forward:

- For Herranz et al. 2006 (65), observed data from VPA administration once daily in the morning and evening are represented in one simulation. As well as the 1 month and 4 months VPA concentration measurements are combined to one timepoint for each study.

Predictive performance of PBPK models was evaluated by 1) calculating the ratio of predicted-toobserved (p/o) PK parameters, and by 2) a visual predictive check (VPC). Ratios within 0.5 to 2-fold range were considered acceptable. For a visual check, observed plasma concentration-time profiles were extracted from literature, digitalized with WebPlotDigitizer v4.6, and compared to predicted plasma concentration-time curves.

#### 4.2 Model verification results

For CBZ and CBZE predictions, the adult p/o PK ratios are shown in Figure S2, the pediatric ratios are shown in Figure S3, whereas for VPA the ratios upon IR administration are provided in Figure S4 and ratios upon ER administration in Figure S5. The percentages of p/o CBZ and CBZE PK ratios that fell within the 2-, 1.5-, and 1.25-fold range are provided in Table S11 and for VPA in Table S12. The VPCs for CBZ and CBZE predictions in adults are shown in Figure S6-7, in pediatrics in Figure S8-9, whereas for VPA IR in Figure S10-12 and for VPA ER in Figure S13-14.

Table 11. Carbamazepine (CBZ) and carbamazepine-10,11-epoxide (CBZE) ratios within 2-, 1.5-, and 1.25-fold range.

	<b>CBZ</b>				<b>CBZE</b>			
	N	2-fold	$1.5-fold$	$1.25$ -fold	N	2-fold	$1.5-fold$	1.25-fold
Adult single	53	66%	40%	23%	17	76%	35%	24%
Adult multi	40	100%	85%	53%	28	86%	54%	39%
Pediatric single	28	82%	43%	25%	0			
Pediatric multi	39	100%	90%	62%	14	79%	79%	71%

	<b>VPA IR</b>				<b>VPA ER</b>				
	N	2-fold	$1.5-fold$	$1.25-fold$	N	2-fold	$1.5-fold$	$1.25-fold$	
Adult single	33	93.9%	90.9%	63.6%	18	88.9%	61.1%	44.4%	
Adult multi	8	100%	100%	87.5%	16	87.5%	87.5%	68.8%	
Pediatric single	18	66.7%	61.1%	61.1%	0				
Pediatric multi	33	87.9%	48.5%	39.4%	10	100%	60.0%	50.0%	

Table 12. Valproic acid (VPA) ratios within 2-, 1.5-, and 1.25-fold range.



Figure 2. Predicted-to-observed ratios of the maximum concentration ( $C_{\text{max}}$ ), minimum concentration ( $C_{\text{min}}$ ), time to peak concentration ( $T_{\text{max}}$ ), area under the curve (AUC), volume of distribution (Vd), clearance (CL), and half-life (t<sub>1/2</sub>) for carbamazepine single- and multi-dose studies in adults. Single symbols represent a predicted-to-observed ratio of a single pharmacokinetic study. The black lines represent the 2-fold range, the dashed lines the 1.5-fold range, the gray shaded area represent the 1.25-fold range and the gray line represents the unity line.



Figure 3. Predicted-to-observed ratios of the maximum concentration (C<sub>max</sub>), minimum concentration (C<sub>min</sub>), average concentration (C<sub>av</sub>), time to peak concentration (T<sub>max</sub>), area under the curve (AUC), volume of distribution (Vd), clearance (CL), and half-life ( $t_{1/2}$ ) for carbamazepine single- and multi-dose studies in pediatrics. Single symbols represent a predicted-to-observed ratio of a single pharmacokinetic study. The black lines represent the 2-fold range, the dashed lines the 1.5-fold range, the gray shaded area represent the 1.25-fold range and the gray line represents the unity line.



Figure 4. Predicted-to-observed ratios of the maximum concentration (C<sub>max</sub>), average concentration (C<sub>av</sub>), minimum concentration (C<sub>min</sub>), time to peak concentration (T<sub>max</sub>), area under the curve (AUC), volume of distribution (Vd), clearance (CL), and half-life (t<sub>1/2</sub>) for valproic acid immediate release formulation single- and multi-dose studies in adults and pediatrics. Single symbols represent a predicted-to-observed ratio of a single pharmacokinetic study. The black lines represent the 2-fold range, the dashed lines the 1.5-fold range, the gray shaded area represent the 1.25-fold range and the gray line represents the unity line.



Predicted-to-observed PK parameter ratio

Figure 5. Predicted-to-observed ratios of the maximum concentration ( $C_{\text{max}}$ ), minimum concentration ( $C_{\text{min}}$ ), time to peak concentration ( $T_{\text{max}}$ ), area under the curve (AUC), volume of distribution (Vd), clearance (CL), and half-life (t<sub>1/2</sub>) for valproic acid extended-release formulations single- and multi-dose studies in adults and pediatrics. Single symbols represent a predicted-to-observed ratio of a single pharmacokinetic study. The black lines represent the 2-fold range, the dashed lines the 1.5-fold range, the gray shaded area represent the 1.25-fold range and the gray line represents the unity line.



Figure 6. Prediction of carbamazepine (CBZ) and carbamazepine-10,11-epoxide (CBZE) plasma concentration-time profiles in adults upon single dose administration. The solid line is the predicted mean of the simulated population and the shaded area represents the 5<sup>th</sup> to 95<sup>th</sup> percentile of the virtual population. Open circles are the observed data: A (13), B (11), C (5-7, 11, 12, 16), D (5), E (4, 9, 14, 15), F (4), G (8, 10, 11), and H (8).





Time (h)



Figure 7. Prediction of carbamazepine (CBZ) and carbamazepine-10,11-epoxide (CBZE) plasma concentration-time profiles in adults upon multi dose administration. The solid line is the predicted mean of the simulated population and the shaded area represents the 5<sup>th</sup> to 95<sup>th</sup> percentile of the virtual population. Open circles are the observed data: A-L (22), M & N (17, 19), O & P (9), Q (11), R & S (18), and T & U (21).



Figure 8. Prediction of carbamazepine (CBZ) and plasma concentration-time profiles in paediatric individuals upon single dose administration. The solid line is the predicted mean of the simulated population and the shaded area represents the 5<sup>th</sup> to 95<sup>th</sup> percentile of the virtual population. Open circles are the observed data: A (23), B (24), C (25), and D & E (26).







Figure 9. Prediction of carbamazepine (CBZ) and carbamazepine-10,11-epoxide (CBZE) plasma concentration-time profiles in paediatric individuals upon multi dose administration. The solid line is the predicted mean of the simulated population and the shaded area represents the 5<sup>th</sup> to 95<sup>th</sup> percentile of the virtual population. Open circles are the observed data: A-D (28), E & F (31), G (29), H & I (33), J & K (34), and L & M (36).





Figure 10. Prediction of (unbound) valproic acid plasma concentration-time profiles in adults upon single-dose immediate-release administration. The solid line is the predicted mean of the simulated population and the shaded area represents the  $5<sup>th</sup>$  to  $95<sup>th</sup>$  percentile of the virtual population. Open circles are the observed data: A & B (37), C (38), D (39), E-G (40), H (41), I (42), and J & K (43).



Figure 11. Prediction of valproic acid (VPA) and 4-ene-VPA plasma concentration-time profiles in adults upon multi-dose immediate-release administration. The solid line is the predicted mean of the simulated population and the shaded area represents the 5<sup>th</sup> to 95<sup>th</sup> percentile of the virtual population. Open circles are the observed data: A & B (44), C & D (38), and E (45).



















Figure 12. Prediction of valproic acid (VPA) plasma concentration-time profiles in pediatrics upon singleand multi-dose immediate release administration. The solid line is the predicted mean of the simulated population and the shaded area represents the  $5<sup>th</sup>$  to  $95<sup>th</sup>$  percentile of the virtual population. Open circles are the observed data: A (48), B (49), C (50), D (48), E-H (54), I & J (55), and K (51).



Figure 13. Prediction of valproic acid (VPA) plasma concentration-time profiles in adults upon singleand multi-dose extended-release administration. The solid line is the predicted mean of the simulated population and the shaded area represents the 5<sup>th</sup> to 95<sup>th</sup> percentile of the virtual population. Open circles are the observed data: A (58), B (59), C (60), D (61), E (62), F (58), and G & H (63).





Figure 14. Prediction of valproic acid (VPA) plasma concentration-time profiles in pediatrics upon multidose extended release administration. The solid line is the predicted mean of the simulated population and the shaded area represents the  $5<sup>th</sup>$  to  $95<sup>th</sup>$  percentile of the virtual population. Open circles are the observed data: A-D (64) and E-I (65).

# <span id="page-31-0"></span>5. Simulating alternative dosing regimens

### *Methods*

After model verification, the models were applied prospectively to evaluate current dosing strategies upon oral administration in children. The current CBZ dosing regimen for epilepsy, as provided in the Dutch Paediatric Formulary (DPF), was simulated (Figure S15-17) (68). Predicted exposures are compared to the therapeutic window of 4-12 μg/ml for CBZ (69), although concerns have been raised that levels above 8 μg/ml may result in reduced cognitive function in children (70). For CBZE, the upper boundary of the reference range, i.e., 2.3 μg/ml, is included (71). To note, for CBZ in the 5-12 year simulation, simulated children weighing over 50, 40, and 33.3 kg received 1000 mg/day after 2, 3, and 4 weeks after start of the therapy, respectively. This applied to 2, 7, and 8 virtual subjects, respectively.

The current VPA dosing regimen for epilepsy, as provided in the DPF, were simulated (Figure S19-23) (72). The same dosing strategies were simulated in term neonates (Figure S21 and 23). Predicted exposures were compared to the therapeutic window of 50-100 μg/ml for VPA (69). Based on reference concentrations of 50-100 μg/ml total VPA, reference values for the free fraction are 4-15 μg/ml (i.e., 7-9% unbound at 50 μg/ml and 15% at 100 μg/ml total concentrations) (3, 73). For 4-ene-VPA, the suggested upper boundary of the reference range, i.e., 0.5 μg/ml, is included (74).

In addition, to determine the effect of altered albumin levels in children and thereby potentially necessitating different dosing strategies, the mean VPA, unbound VPA, and 4-ene-VPA concentrations were simulated under +20%, normal, -20%, and -35% altered albumin level conditions (Figure S24). The coefficient of variance (CV) % was set to zero. In addition, the (hepatic) clearances (Figure S25) and volume of distributions were plotted (Figure S26).



Figure 15. Prediction of carbamazepine (CBZ) and carbamazepine-10,11-epoxide (CBZE) concentrations following the current dosing guideline in children aged 12 to 16 and 16 to 18 years. The dose increases with 200 mg/day each week, with a maximum of 1000 mg/day and 1200 mg/day, respectively. The black solid line is the predicted mean of the simulated population and the gray shaded area represents the 5<sup>th</sup> to 95<sup>th</sup> percentile of the virtual population. The blue shaded area indicates the CBZ therapeutic window (i.e., 4-12 μg/ml) and the red solid line indicates the CBZE upper boundary of the reference range (i.e., 2.3 μg/ml).



Figure 16. Prediction of carbamazepine (CBZ) and carbamazepine-10,11-epoxide (CBZE) concentrations following the current dosing guideline in children aged 1 to 5 and 5 to 12 years. The dose increases with 5 mg/kg/day each week, with a maximum of 35 mg/kg/day and 1000 mg/day, respectively. The black solid line is the predicted mean of the simulated population and the gray shaded area represents the 5<sup>th</sup> to 95<sup>th</sup> percentile of the virtual population. The blue shaded area indicates the CBZ therapeutic window (i.e., 4-12 μg/ml) and the red solid line indicates the CBZE upper boundary of the reference range (i.e., 2.3 μg/ml).



Figure 17. Prediction of carbamazepine (CBZ) and carbamazepine-10,11-epoxide (CBZE) concentrations following the current dosing guideline in children aged 0 to 1 month and 1 month to 1 year. The dose increases with 5 mg/kg/day each week, with a maximum of 15 mg/kg/day (where the 7 mg/kg/day dosing regimen first changes to a 10 mg/kg/day regimen) and with a maximum of 35 mg/kg/day, respectively. The black solid line is the predicted mean of the simulated population and the gray shaded area represents the 5<sup>th</sup> to 95<sup>th</sup> percentile of the virtual population. The blue shaded area indicates the CBZ therapeutic window (i.e., 4-12 μg/ml) and the red solid line indicates the CBZE upper boundary of the reference range (i.e., 2.3 μg/ml).



Figure 18. Prediction of carbamazepine (CBZ) and carbamazepine-10,11-epoxide (CBZE) concentrations following the current and an adjusted dosing scheme in children aged 12 to 16 years and 16 to 18 years. The dose increases with 200 mg/day each week. The black solid line is the predicted mean of the simulated population and the gray shaded area represents the 5<sup>th</sup> to 95<sup>th</sup> percentile of the virtual population. The blue shaded area indicates the CBZ therapeutic window (i.e., 4-12 μg/ml) and the red solid line indicates the CBZE upper boundary of the reference range (i.e., 2.3 μg/ml).



<span id="page-36-0"></span>Figure 19. Prediction of valproic acid (VPA), unbound VPA, and 4-ene-VPA concentrations following the current dosing guideline in children aged 5 to 18 years. The dose increases with 10 mg/kg/day each week, with a maximum of 30 mg/kg/day. The black solid line is the predicted mean of the simulated population and the gray shaded area represents the 5<sup>th</sup> to 95<sup>th</sup> percentile of the virtual population. The blue shaded area indicates the VPA therapeutic window (i.e., 50-100 μg/ml), the green shaded area indicated the unbound VPA therapeutic window (i.e., 4-15 μg/ml), and the red solid line indicates the 4 ene-VPA upper boundary of the reference range (i.e., 0.5 μg/ml).



Figure 20. Prediction of valproic acid (VPA), unbound VPA, and 4-ene-VPA concentrations following the current dosing guideline in children aged 1 month to 5 years. The dose increases with 10 mg/kg/day each week, with a maximum of 30 mg/kg/day. The black solid line is the predicted mean of the simulated population and the gray shaded area represents the 5<sup>th</sup> to 95<sup>th</sup> percentile of the virtual population. The blue shaded area indicates the VPA therapeutic window (i.e., 50-100 μg/ml), the green shaded area indicated the unbound VPA therapeutic window (i.e., 4-15 μg/ml), and the red solid line indicates the 4 ene-VPA upper boundary of the reference range (i.e., 0.5 μg/ml).



Figure 21. Prediction of valproic acid (VPA), unbound VPA, and 4-ene-VPA concentrations following the current dosing guideline in children aged 0 to 1 month. The dose increases with 10 mg/kg/day each week, with a maximum of 30 mg/kg/day. The black solid line is the predicted mean of the simulated population and the gray shaded area represents the 5<sup>th</sup> to 95<sup>th</sup> percentile of the virtual population. The blue shaded area indicates the VPA therapeutic window (i.e., 50-100 μg/ml), the green shaded area indicated the unbound VPA therapeutic window (i.e., 4-15 μg/ml), and the red solid line indicates the 4 ene-VPA upper boundary of the reference range (i.e., 0.5 μg/ml).



Figure 22. Prediction of valproic acid (VPA) and unbound VPA concentrations following the current extended release dosing guideline in children aged 1 month to 18 years. The dose increases with 10 mg/kg/day each week, with a maximum of 30 mg/kg/day. The black solid line is the predicted mean of the simulated population and the gray shaded area represents the 5<sup>th</sup> to 95<sup>th</sup> percentile of the virtual population. The blue shaded area indicates the VPA therapeutic window (i.e., 50-100 μg/ml) and the green shaded area indicated the unbound VPA therapeutic window (i.e., 4-15 μg/ml).



Figure 23. Prediction of valproic acid (VPA) and unbound VPA concentrations following the current extended release dosing guideline in children aged 0 to 1 month without 'redefine subjects over time' function. The dose increases with 10 mg/kg/day each week, with a maximum of 30 mg/kg/day. The black solid line is the predicted mean of the simulated population and the gray shaded area represents the 5<sup>th</sup> to 95<sup>th</sup> percentile of the virtual population. The blue shaded area indicates the VPA therapeutic window (i.e., 50-100 μg/ml) and the green shaded area indicated the unbound VPA therapeutic window (i.e., 4-15 μg/ml).



Figure 24. Prediction of valproic acid (VPA) and unbound VPA concentrations following 10 mg/kg immediate release VPA every 12 hours (q12h) in children aged 0 to 18 years with varying human serum albumin (HSA) levels. The lines are the predicted means of the simulated populations. The blue shaded area indicates the VPA therapeutic window (i.e., 50-100 μg/ml) and the green shaded area indicates the unbound VPA therapeutic window (i.e., 4-15 μg/ml).



Figure 25. Violin plots of predicted valproic acid clearance (CL) and hepatic clearance (CL<sub>h</sub>) values upon either altered human serum albumin (HSA) levels, or altered doses, or both per simulated individual (n = 100, 12-18 years). Median levels are shown on top.



Figure 26. Predicted volume of distributions over time upon either altered human serum albumin (HSA) levels, or altered doses, or both. The lines are the predicted means of the simulated populations (n = 100, 12-18 years).



Figure 27. Predicted and observed valproic acid clearances (CL) corrected for body weight A) across the whole pediatric age range, and B) from 0 to 2 years old. The grey dots are individual predicted clearances after 3 weeks of treatment. For neonates, predicted clearances were provided upon a first dose and after 5 weeks of treatment. Observed data are either individual data points, or an average clearance with standard deviation across a certain age range., i.e., indicated with a connecting line. Observed data: Brachet-Liermain (51), Alfonso (46), Gal (53), Irvine-Meek (75), Herngren (54), Hall (48), Taylor (76), Kriel (77), Panomvana (78), Serrano (79), Cloyd (47), and Dutta (64).

# 6. References

- 1. Huang YT, Huang YM, Kung FL, Lin CJ, Jao T, Ho YF. Physiologically based mechanistic insight into differential risk of valproate hepatotoxicity between children and adults: A focus on ontogeny impact. CPT Pharmacometrics Syst Pharmacol. 2023;12(12):1960-71.
- 2. Conner TM, Nikolian VC, Georgoff PE, Pai MP, Alam HB, Sun D, et al. Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex. Eur J Pharm Sci. 2018;111:465-81.
- 3. Cloyd JC, Dutta S, Cao G, Walch JK, Collins SD, Granneman GR. Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy. Epilepsy Research. 2003;53(1):19-27.
- 4. Barzaghi N, Gatti G, Crema F, Monteleone M, Amione C, Leone L, Perucca E. Inhibition by erythromycin of the conversion of carbamazepine to its active 10,11-epoxide metabolite. Br J Clin Pharmacol. 1987;24(6):836-8.
- 5. Bedada SK, Nearati P. Effect of resveratrol on the pharmacokinetics of carbamazepine in healthy human volunteers. Phytother Res. 2015;29(5):701-6.
- 6. Bedada SK, Appani R, Boga PK. Effect of Piperine on the Metabolism and Pharmacokinetics of Carbamazepine in Healthy Volunteers. Drug Res (Stuttg). 2017;67(1):46-51.
- 7. Bedada SK, Boga PK. Influence of diosmin on the metabolism and disposition of carbamazepine in healthy subjects. Xenobiotica. 2017;47(10):879-84.
- 8. Bernus I, Dickinson RG, Hooper WD, Eadie MJ. Early stage autoinduction of carbamazepine metabolism in humans. Eur J Clin Pharmacol. 1994;47(4):355-60.
- 9. Chan KK, Sawchuk RJ, Thompson TA, Redalieu E, Wagner WE, Jr., LeSher AR, et al. Bioequivalence of carbamazepine chewable and conventional tablets: single-dose and steady-state studies. J Pharm Sci. 1985;74(8):866-70.
- 10. Dalton MJ, Powell JR, Messenheimer JA, Jr. The influence of cimetidine on single-dose carbamazepine pharmacokinetics. Epilepsia. 1985;26(2):127-30.
- 11. Géradin AP, Abadie FV, Campestrini JA, Theobald W. Pharmacokinetics of carbamazepine in normal humans after single and repeated oral doses. J Pharmacokinet Biopharm. 1976;4(6):521-35.
- 12. Maas B, Garnett WR, Pellock JM, Comstock TJ. A comparative bioavailability study of carbamazepine tablets and a chewable tablet formulation. Ther Drug Monit. 1987;9(1):28-33.
- 13. Marino SE, Birnbaum AK, Leppik IE, Conway JM, Musib LC, Brundage RC, et al. Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. Clin Pharmacol Ther. 2012;91(3):483-8.
- 14. Pynnönen S. The pharmacokinetics of carbamazepine in plasma and saliva of man. Acta Pharmacol Toxicol (Copenh). 1977;41(5):465-71.
- 15. Pynnönen S, Mäntylä R, Iisalo E. Bioavailability of four different pharmaceutical preparations of carbamazepine. Acta Pharmacol Toxicol (Copenh). 1978;43(4):306-10.
- 16. Wada JA, Troupin AS, Friel P, Remick R, Leal K, Pearmain J. Pharmacokinetic comparison of tablet and suspension dosage forms of carbamazepine. Epilepsia. 1978;19(3):251-5.
- 17. Burstein AH, Horton RL, Dunn T, Alfaro RM, Piscitelli SC, Theodore W. Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther. 2000;68(6):605-12.
- 18. Ji P, Damle B, Xie J, Unger SE, Grasela DM, Kaul S. Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. J Clin Pharmacol. 2008;48(8):948-56.
- 19. Møller SE, Larsen F, Khant AZ, Rolan PE. Lack of effect of citalopram on the steady-state pharmacokinetics of carbamazepine in healthy male subjects. J Clin Psychopharmacol. 2001;21(5):493-9.
- 20. Moreno J, Belmont A, Jaimes O, Santos JA, López G, Campos MG, et al. Pharmacokinetic study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment. Arch Med Res. 2004;35(2):168-71.
- 21. Patsalos PN. A comparative pharmacokinetic study of conventional and chewable carbamazepine in epileptic patients. Br J Clin Pharmacol. 1990;29(5):574-7.
- 22. Tolbert D, Cloyd J, Biton V, Bekersky I, Walzer M, Wesche D, et al. Bioequivalence of oral and intravenous carbamazepine formulations in adult patients with epilepsy. Epilepsia. 2015;56(6):915- 23.
- 23. Bano G, Raina RK, Sharma DB. Pharmacokinetics of carbamazepine in protein energy malnutrition. Pharmacology. 1986;32(4):232-6.
- 24. Bertilsson L, Höjer B, Tybring G, Osterloh J, Rane A. Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin Pharmacol Ther. 1980;27(1):83-8.
- 25. MacKintosh DA, Baird-Lampert J, Buchanan N. Is carbamazepine an alternative maintenance therapy for neonatal seizures? Dev Pharmacol Ther. 1987;10(2):100-6.
- 26. Rey E, d'Athis P, de Lauture D, Dulac O, Aicardi J, Olive G. Pharmacokinetics of carbamazepine in the neonate and in the child. Int J Clin Pharmacol Biopharm. 1979;17(2):90-6.
- 27. Singh B, Singh P, al Hifzi I, Khan M, Majeed-Saidan M. Treatment of neonatal seizures with carbamazepine. J Child Neurol. 1996;11(5):378-82.
- 28. Camfield P, Hwang P, Camfield C, Fraser A, Soldin S, al-Quadah AK. The pharmacology of chewable versus regular carbamazepine in chronically treated children with epilepsy. Can J Neurol Sci. 1992;19(2):204-7.
- 29. Carlsson KC, Hoem NO, Glauser T, Vinks AA. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy. Clin Ther. 2005;27(5):618-26.
- 30. Cornaggia C, Gianetti S, Battino D, Granata T, Romeo A, Viani F, Limido G. Comparative pharmacokinetic study of chewable and conventional carbamazepine in children. Epilepsia. 1993;34(1):158-60.
- 31. Eeg-Olofsson O, Nilsson HL, Tonnby B, Arvidsson J, Grahn PA, Gylje H, et al. Diurnal variation of carbamazepine and carbamazepine-10,11-epoxide in plasma and saliva in children with epilepsy: a comparison between conventional and slow-release formulations. J Child Neurol. 1990;5(2):159- 65.
- 32. Furlanut M, Montanari G, Bonin P, Casara GL. Carbamazepine and carbamazepine-10,11-epoxide serum concentrations in epileptic children. J Pediatr. 1985;106(3):491-5.
- 33. Hartley R, Forsythe WI, McLain B, Ng PC, Lucock MD. Daily variations in steady-state plasma concentrations of carbamazepine and its metabolites in epileptic children. Clin Pharmacokinet. 1991;20(3):237-46.
- 34. Hartley R, Aleksandrowicz J, Bowmer CJ, Cawood A, Forsythe WI. Dissolution and relative bioavailability of two carbamazepine preparations for children with epilepsy. J Pharm Pharmacol. 1991;43(2):117-9.
- 35. Reith DM, Appleton DB, Hooper W, Eadie MJ. The effect of body size on the metabolic clearance of carbamazepine. Biopharm Drug Dispos. 2000;21(3):103-11.
- 36. Thakker KM, Mangat S, Garnett WR, Levy RH, Kochak GM. Comparative bioavailability and steady state fluctuations of Tegretol commercial and carbamazepine OROS tablets in adult and pediatric epileptic patients. Biopharm Drug Dispos. 1992;13(8):559-69.
- 37. Bialer M, Hussein Z, Raz I, Abramsky O, Herishanu Y, Pachys F. Pharmacokinetics of valproic acid in volunteers after a single dose study. Biopharm Drug Dispos. 1985;6(1):33-42.
- 38. Cheng H, Liu Z, Blum W, Byrd JC, Klisovic R, Grever MR, et al. Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;850(1-2):206-12.
- 39. Chun AH, Hoffman DJ, Friedmann N, Carrigan PJ. Bioavailability of valproic acid under fasting/nonfasting regimens. J Clin Pharmacol. 1980;20(1):30-6.
- 40. Georgoff PE, Nikolian VC, Bonham T, Pai MP, Tafatia C, Halaweish I, et al. Safety and Tolerability of Intravenous Valproic Acid in Healthy Subjects: A Phase I Dose-Escalation Trial. Clin Pharmacokinet. 2018;57(2):209-19.
- 41. Gugler R, Schell A, Eichelbaum M, Fröscher W, Schulz HU. Disposition of valproic acid in man. Eur J Clin Pharmacol. 1977;12(2):125-32.
- 42. Nitsche V, Mascher H. The Pharmacokinetics of Valproic Acid After Oral and Parenteral Administration in Healthy Volunteers. Epilepsia. 1982;23(2):153-62.
- 43. Perucca E, Gatti G, Frigo GM, Crema A. Pharmacokinetics of valproic acid after oral and intravenous administration. Br J Clin Pharmacol. 1978;5(4):313-8.
- 44. Addison RS, Parker-Scott SL, Eadie MJ, Hooper WD, Dickinson RG. Steady-state dispositions of valproate and diflunisal alone and coadministered to healthy volunteers. Eur J Clin Pharmacol. 2000;56(9-10):715-21.
- 45. Hussein Z, Mukherjee D, Lamm J, Cavanaugh JH, Granneman GR. Pharmacokinetics of valproate after multiple-dose oral and intravenous infusion administration: gastrointestinal-related diurnal variation. J Clin Pharmacol. 1994;34(7):754-9.
- 46. Alfonso I, Alvarez LA, Gilman J, Dunoyer C, Yelin K, Papazian O. Intravenous valproate dosing in neonates. J Child Neurol. 2000;15(12):827-9.
- 47. Cloyd JC, Kriel RL, Fischer JH, Sawchuk RJ, Eggerth RM. Pharmacokinetics of valproic acid in children: I. Multiple antiepileptic drug therapy. Neurology. 1983;33(2):185-91.
- 48. Hall K, Otten N, Irvine-Meek J, Leroux M, Budnick D, Verma M, Seshia SS. First-dose and steadystate pharmacokinetics of valproic acid in children with seizures. Clin Pharmacokinet. 1983;8(5):447-55.
- 49. Visudtibhan A, Bhudhisawadi K, Vaewpanich J, Chulavatnatol S, Kaojareon S. Pharmacokinetics and clinical application of intravenous valproate in Thai epileptic children. Brain Dev. 2011;33(3):189- 94.
- 50. Williams JH, Jayaraman B, Swoboda KJ, Barrett JS. Population pharmacokinetics of valproic acid in pediatric patients with epilepsy: considerations for dosing spinal muscular atrophy patients. J Clin Pharmacol. 2012;52(11):1676-88.
- 51. Brachet-Liermain, A., et al, Pharmacokinetics of dipropyl acetate in infants and young children, Pharmaceutisch Weekblad, 1977, 112, 293-97.
- 52. Chiba K, Suganuma T, Ishizaki T, Iriki T, Shirai Y, Naitoh H, Hori M. Comparison of steady-state pharmacokinetics of valproic acid in children between monotherapy and multiple antiepileptic drug treatment. J Pediatr. 1985;106(4):653-8.
- 53. Gal P, Oles KS, Gilman JT, Weaver R. Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures. Neurology. 1988;38(3):467-71.
- 54. Herngren L, Lundberg B, Nergårdh A. Pharmacokinetics of total and free valproic acid during monotherapy in infants. J Neurol. 1991;238(6):315-9.
- 55. Lundberg B, Nergårdh A, Boréus LO. Plasma concentrations of valproate during maintenance therapy in epileptic children. J Neurol. 1982;228(2):133-41.
- 56. Su JM, Li XN, Thompson P, Ou CN, Ingle AM, Russell H, et al. Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. Clin Cancer Res. 2011;17(3):589-97.
- 57. Zhao M, Zhang T, Li G, Qiu F, Sun Y, Zhao L. Simultaneous Determination of Valproic Acid and Its Major Metabolites by UHPLC-MS/MS in Chinese Patients: Application to Therapeutic Drug Monitoring. J Chromatogr Sci. 2017;55(4):436-44.
- 58. Dulac O, Alvarez JC. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration. Pharmacotherapy. 2005;25(1):35-41.
- 59. Dutta S, Zhang Y, Lee LL, O'Dea R. Comparison of the bioavailability of 250 and 500 mg divalproex sodium extended-release tablets in healthy volunteers. Biopharm Drug Dispos. 2004;25(8):353-7.
- 60. Dutta S, Reed RC, Cavanaugh JH. Absolute Bioavailability and Absorption Characteristics of Divalproex Sodium Extended-Release Tablets in Healthy Volunteers. The Journal of Clinical Pharmacology. 2004;44(7):737-42.
- 61. Qiu Y, Cheskin HS, Engh KR, Poska RP. Once‐a‐Day Controlled‐Release Dosage form of Divalproex Sodium I: Formulation Design and in Vitro/in Vivo Investigations. Journal of Pharmaceutical Sciences. 2003;92(6):1166-73.
- 62. Cawello W, Bonn R. No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers. J Clin Pharmacol. 2012;52(11):1739-48.
- 63. Dutta S, Zhang Y, Selness DS, Lee LL, Williams LA, Sommerville KW. Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayedrelease formulation in healthy volunteers. Epilepsy Research. 2002;49(1):1-10.
- 64. Dutta S, Zhang Y, Conway JM, Sallee FR, Biton V, Reed MD, Kearns GL. Divalproex-ER pharmacokinetics in older children and adolescents. Pediatr Neurol. 2004;30(5):330-7.
- 65. Herranz JL, Arteaga R, Adín J, Armijo JA. Conventional and sustained-release valproate in children with newly diagnosed epilepsy: a randomized and crossover study comparing clinical effects, patient preference and pharmacokinetics. Eur J Clin Pharmacol. 2006;62(10):805-15.
- 66. van der Heijden JEM, Freriksen JJM, de Hoop-Sommen MA, van Bussel LPM, Driessen SHP, Orlebeke AEM, et al. Feasibility of a Pragmatic PBPK Modeling Approach: Towards Model-Informed Dosing in Pediatric Clinical Care. Clin Pharmacokinet. 2022;61(12):1705-17.
- 67. van der Heijden JEM, Freriksen JJM, de Hoop-Sommen MA, Greupink R, de Wildt SN. Physiologically-Based Pharmacokinetic Modeling for Drug Dosing in Pediatric Patients: A Tutorial for a Pragmatic Approach in Clinical Care. Clin Pharmacol Ther. 2023;114(5):960-71.
- 68. Kinderformularium. Kinderformularium Carbamazepine [updated 15 July 2019] Date cited: 14 December 2023. 2023. Available **Southern Strategy** [https://www.kinderformularium.nl/geneesmiddel/202/carbamazepine.](https://www.kinderformularium.nl/geneesmiddel/202/carbamazepine)
- 69. Patsalos PN, Spencer EP, Berry DJ. Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update. Ther Drug Monit. 2018;40(5):526-48.
- 70. Walson PD. Role of therapeutic drug monitoring (TDM) in pediatric anti-convulsant drug dosing. Brain Dev. 1994;16(1):23-6.
- 71. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs- -best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239-76.
- 72. Kinderformularium. Kinderformularium Valproïnezuur (Natriumvalproaat) [updated 17 October 2020] Date cited: 14 December 2023. Available from: [https://www.kinderformularium.nl/geneesmiddel/217/valpronezuur-natriumvalproaat.](https://www.kinderformularium.nl/geneesmiddel/217/valpronezuur-natriumvalproaat)
- 73. Nederlandse Vereniging van Ziekenhuisapothekers (NVZA). *TDM Monografie - Valproïnezuur* [Last updated: 08-03-2019]. Available from[: https://tdm-monografie.org/valproinezuur/](https://tdm-monografie.org/valproinezuur/) [
- 74. Kondo T, Kaneko S, Otani K, Ishida M, Hirano T, Fukushima Y, et al. Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism. Epilepsia. 1992;33(1):172-7.
- 75. Irvine-Meek JM, Hall KW, Otten NH, Leroux M, Budnik D, Seshia SS. Pharmacokinetic study of valproic acid in a neonate. Pediatr Pharmacol (New York). 1982;2(4):317-21.
- 76. Taylor LM, Farzam F, Cook AM, Lewis DA, Baumann RJ, Kuhn RJ. Clinical utility of a continuous intravenous infusion of valproic acid in pediatric patients. Pharmacotherapy. 2007;27(4):519-25.
- 77. Kriel RL, Fischer JH, Cloyd JC, Green KH, Fraser GL. Valproic acid pharmacokinetics in children: III. Very high dosage requirements. Pediatr Neurol. 1986;2(4):202-8.
- 78. Panomvana Na Ayudhya D, Suwanmanee J, Visudtibhan A. Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children. Am J Ther. 2006;13(3):211-7.
- 79. Serrano BB, García Sánchez MJ, Otero MJ, Buelga DS, Serrano J, Domínguez-Gil A. Valproate population pharmacokinetics in children. J Clin Pharm Ther. 1999;24(1):73-80.